Table 2.

Univariate analysis

Characteristic	PFS		OS
	HR (95% CI)	P	HR (95% CI)	P
Age	1.01 (0.98-1.04)	.425	1.05 (0.99-1.11)	.107
Male	3.73 (0.86-16.30)	.080	1.65 (0.19-14.20)	.648
Stage II	1.26 (0.45-3.53)	.665	2.4 (0.28-20.65)	.425
ECOG PS 1	1.04 (0.30-3.62)	.951	0.04 (0.00-265.72)	.461
Supradiaphragmatic disease	3.49 (0.80-15.24)	.097	31.38 (0.01-85 218.00)	.393
B symptoms	0.63 (0.08-4.80)	.630	0.05 (0.00-82 523.70)	.673
Extranodal disease	0.64 (0.08-4.90)	.670	2.79 (0.32-24.07)	.351
Variant histologic pattern	0.65 (0.24-1.82)	.417	0.39 (0.05-3.33)	.39
PET-CT imaging not performed	3.16 (1.24-8.04)	.016	4.38 (0.74-25.88)	.104
Tumor size ≥5 cm	0.95 (0.27-3.34)	.931	0.89 (0.10-7.65)	.913
Era of therapy
Before 2000*
2000-2010	0.55 (0.20-1.50)	.240	0.38 (0.08-1.97)	.251
2011-2017	0.24 (0.03-2.22)	.210	<0.01 (0.00-1.6 × 10172)	.957

HR, hazard ratio.

^*The reference category is treatment before 2000.